Rui Avelar - 19 Mar 2024 Form 4 Insider Report for Evolus, Inc. (EOLS)

Role
Chief Medical Officer & Head of Research and Development
Signature
/s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar
Issuer symbol
EOLS
Transactions as of
19 Mar 2024
Net transactions value
-$384,350
Form type
4
Filing time
21 Mar 2024, 18:09:35 UTC
Previous filing
23 Feb 2024
Next filing
14 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EOLS Common Stock Sale $384,350 -27,603 -6.9% $13.92 372,288 19 Mar 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were mandated by the Issuer pursuant to Restricted Stock Unit Agreements requiring the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction, and does not represent a discretionary trade by the reporting person.
F2 The shares were sold in multiple trades at prices ranging from $13.555 to $14.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

Chief Medical Officer & Head of Research and Development